中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
22期
3410-3412
,共3页
髓系抗原%白血病,淋巴细胞,急性%成年人
髓繫抗原%白血病,淋巴細胞,急性%成年人
수계항원%백혈병,림파세포,급성%성년인
Myeloid antigen%Leukemia,lymphocytic,acute%Adult
目的 探讨急性淋巴细胞白血病(ALL)患者髓系抗原表达与临床特征、预后的关系及意义.方法 回顾性分析103例初治ALL患者的临床资料,根据流式细胞术免疫分型分为髓系抗原阳性表达(MyAg+ ALL)和阴性表达(MyAg ALL),分析髓系抗原表达与临床特征、近期疗效及5年总生存率的关系.结果 103例ALL患者中,髓系抗原表达占46.5％,以CD13、CD33为主,分别为34.2％、21.4％；CD34在MyAg+ALL中表达率高于MyAg－ALL组(75.3％与60.5％,P＜0.05)；髓系抗原表达在T-ALL高于B-ALL(66.7％与42.8％,P＜0.05)；MyAg+ ALL患者形态学分型与免疫学分型不相符率(12.3％)明显高于MyAg ALL(0.0％).结论 ALL髓系抗原表达与ALL患者临床特征、预后无明显关系.
目的 探討急性淋巴細胞白血病(ALL)患者髓繫抗原錶達與臨床特徵、預後的關繫及意義.方法 迴顧性分析103例初治ALL患者的臨床資料,根據流式細胞術免疫分型分為髓繫抗原暘性錶達(MyAg+ ALL)和陰性錶達(MyAg ALL),分析髓繫抗原錶達與臨床特徵、近期療效及5年總生存率的關繫.結果 103例ALL患者中,髓繫抗原錶達佔46.5％,以CD13、CD33為主,分彆為34.2％、21.4％；CD34在MyAg+ALL中錶達率高于MyAg－ALL組(75.3％與60.5％,P＜0.05)；髓繫抗原錶達在T-ALL高于B-ALL(66.7％與42.8％,P＜0.05)；MyAg+ ALL患者形態學分型與免疫學分型不相符率(12.3％)明顯高于MyAg ALL(0.0％).結論 ALL髓繫抗原錶達與ALL患者臨床特徵、預後無明顯關繫.
목적 탐토급성림파세포백혈병(ALL)환자수계항원표체여림상특정、예후적관계급의의.방법 회고성분석103례초치ALL환자적림상자료,근거류식세포술면역분형분위수계항원양성표체(MyAg+ ALL)화음성표체(MyAg ALL),분석수계항원표체여림상특정、근기료효급5년총생존솔적관계.결과 103례ALL환자중,수계항원표체점46.5％,이CD13、CD33위주,분별위34.2％、21.4％；CD34재MyAg+ALL중표체솔고우MyAg－ALL조(75.3％여60.5％,P＜0.05)；수계항원표체재T-ALL고우B-ALL(66.7％여42.8％,P＜0.05)；MyAg+ ALL환자형태학분형여면역학분형불상부솔(12.3％)명현고우MyAg ALL(0.0％).결론 ALL수계항원표체여ALL환자림상특정、예후무명현관계.
Objective To investigate the expression of myeloid antigen(MyAg) in acute lymphoblastic leukemia (ALL) and its correlation with clinical characteristics and prognosis.Methods The clinical data of 103 newly diagnosed ALL 1patients were retrospectively analyzed.These patients were divided into myeloid antigen-positive group (MyAg+ ALL) and myeloid antigen-negative group(MyAgALL) based on the flow cytometry(FCM) analysis in bone marrow.The correlation of MyAg expression with the clinical features,short-term efficacy and 5-year overall survival were assessed in the two groups.Results MyAg expression was detected in 46.5％ out of 103 cases and CD13,CD33 were the most commonly expressed MyAg(34.2％ and 21.4％ respectively).The expression of CD34 in MyAg+ ALL group was higher than MyAgALL group(75.3％ vs 60.5％,P ＜0.05).The expression of MyAg in T-ALL group (66.7％) was higher than B-ALL group (42.8％) (P ＜ 0.05).The clinical and biological characteristics of ALL patients between MyAg+ and MyAggroups showed that higher percentage of incoincidence of classification between morphology and immunology.Conclusion MyAg expression was not correlated with clinical characteristics and prognosis of ALL patients.
